Metastatic prostate cancer is frequent in elderly patients. Initial treatment is based on hormone-deprivation treatment. Resistance however occurs and several treatments have been developed and approved for castration-resistant prostate cancer, such as chemotherapy (docetaxel, cabazitaxel), new hormonal treatments (abiraterone, enzalutamide), and bone-targeting agents. These drugs have been studied in large phase III trials, and seem safe and effective even in older men; however, only fit elderly patients were enrolled in the pivotal trials.
Prostate cancers are a frequently occurring tumor in which incidence increases with age. In 2008, there were around 65,000 new cases in France. Median age at diagnosis is 68 years and 27 % of patients are 75 years of age or more. 1 Most deaths from prostate cancer (70 %) occur in men over 75.
Treatment of metastatic prostate cancer is an oncogeriatric problem, 2 and is palliative, at any age. Initial treatment is based on androgen deprivation.
The most frequent method is chemical castration with luteinizinghormone-releasing hormone (LHRH) agonists or, more recently, LHRH
antagonists. Surgical castration is still offered to some patients. 3 Most patients respond initially, however, resistance occurs. Median hormone sensitivity is around 18 to 24 months.
Until 2010, the only drug that had shown an overall survival (OS) benefit in patients with metastatic castration prostate cancer (mCRPC) was docetaxel. Since then, several new drugs have been developed: new hormone therapies (such as abiraterone acetate and enzalutamide), new chemotherapy agents (cabazitaxel), new bone-targeting agents (denosumab, radium-223), and new immunotherapies. In this article, we will review how to evaluate elderly patients with mCRPC, what data are available on the different treatments, and how we can predict toxicity.
Geriatric Evaluation and Decision-making
The majority of advanced prostate cancer patients are elderly. The trials conducted to determine the effect and toxicity of drugs in the treatment of mCRPC have followed the recommendations generally used for clinical trials: good performance status (PS); no major comorbidities-i.e.
everything that is not common in elderly patients. It is therefore warranted to establish recommendations for the management of elderly patients with mCRPC. Few have been published: the National Comprehensive Cancer Network (NCCN) has determined the impact of geriatric characteristics on decision-making process; the International Society for Geriatric Oncology (SIOG) has published extensive guidelines and a shorter version for clinical use both in the setting of localized and advanced prostate cancer. 4 • Dependence status. There is evidence that the level of dependence in daily living activities influences survival in senior adult patients. 8 Dependence may be easily evaluated using the ADL 9 and the IADL scales.
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The ADL scale rates the patient's ability to accomplish basic activities of daily living (bathing, dressing, toileting, transferring, continence, and feeding). One ADL impairment is considered abnormal in senior adult patients with prostate cancer, with the exception of incontinence. ADL impairment may be reversible through specific geriatric intervention.
The IADL scale rates activities that require a higher level of cognition and judgment. Four items apply to men with prostate cancer: ability to manage money, to manage medications, to use transportation, and to use the telephone. One IADL impairment is considered abnormal. It is unlikely that geriatric intervention would be able to reverse IADL impairment.
• Nutritional status. Malnutrition has also been shown to be associated with increased mortality in senior adult patients. 11 Nutritional status can be estimated simply by the variation of weight during the previous 3 months: good nutritional status: <5 % of weight loss; risk for malnutrition: weight loss between 5 and 10 %; severe malnutrition:
weight loss >10 %. Geriatric intervention could be implemented to reverse malnutrition.
Therefore, the SIOG Prostate Cancer Working Group recommended that the decision-making process in senior adult patients with prostate cancer should be based on a systematic evaluation of comorbidities (CISR-G scale), dependence status (IADL and ADL scales), and nutritional status (weight-loss estimation). In case of vulnerability and frailty, additional geriatric interventions, including a CGA, may be required. 4 This allows senior adult patients with prostate cancer to be classified into four health status categories as described by Balducci et al. 12 They are summarized in Table 1 .
Since 2010, other important studies have been published on the different tools to screen health status in elderly people. These tools have been described for several years and have often been compared with the CGA: the most important are the Groningen Frailty Index (GRI) 13, 14 and the Vulnerable Elders Survey (VES-13). 15, 16 A large national study (ONCODAGE) was performed in France, which involved 1,600 patients and compared the G8 tool and the VES-13 to a CGA. 17, 18 The G8 screening tool comprises eight items. It is performed in a median time of 4.4 minutes.
It is used to identify healthy patients ('fit patients' group). The other patients ('unfit' according to the G8) should have some kind of geriatric evaluation to specifically study individual impairment, more precisely, comorbidities, nutritional status, cognitive and thymic functions, and, importantly, physical functions. The objective of this assessment should be to determine whether geriatric intervention could reverse impairment.
Patients with reversible impairments ('vulnerable patients' group) should be eligible to standard treatment and those with irreversible impairments ('frail patients' group) should receive adapted treatment. All of these patients would also benefit from geriatric intervention to increase their health conditions. A specific group of experts of the SIOG is working on the objective to determine a practical procedure to help the physician in the decision-making. However, there are only incomplete data to define exactly the criteria that should be used: in many cases the guidelines are based on expert consensus more than on evidence in the field of health status evaluation. The refinement of the decision-making process requires new discussions and consensus.
Treatment of Metastatic Castration-resistant Prostate Cancer

Docetaxel-The Backbone of Treatment of Metastatic Castration-resistant Prostate Cancer
Until 2004, mitoxantrone chemotherapy was the standard of care for patients with mCRPC. Compared with prednisone alone it improved symptom control but not OS. 19 The TAX-327 trial compared two schedules of docetaxel (three weekly or weekly) + prednisone to mitoxantrone + prednisone. 20 The median age in the trial was 68 years; 20 % of patients were 75 or older. However, patients had to be fit enough to meet the inclusion criteria (Karnofsky PS ≥60 %, no other serious medical condition, normal cardiac function, and creatinine levels <1. 
New Hormone Therapies Abiraterone Acetate
Abiraterone acetate is a CYP 17 inhibitor that decreases adrenal, testicular, and intratumoral testosterone synthesis, studied in two large phase III trials in patients with mCRPC, in both the predocetaxel setting (in asymptomatic or mildly symptomatic patients) and in the postdocetaxel setting.
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In the COU-AA-301 trial, patients with mCRPC who had progressed during or after docetaxel were randomized between receiving abiraterone + prednisone and placebo + prednisone. 22, 23 There were several exclusion criteria that are important to consider when treating elderly patients.
Patients with abnormal LFTs, with a serum creatinine ≥1.5 x ULN, calculated creatinine clearance <60 ml/minute, chronic liver disease or uncontrolled hypertension, clinically significant heart disease, or using aldactone, spironolactone, and drugs metabolized by the CYP2D6 and 1A2 were excluded. The median age in the trial was 69 years (range:
39-95), more than a quarter of the patients were older than 75.
Patients receiving abiraterone had better OS (HR=0.74, 95 % CI [0.64-0.86]; p<0.0001). They also had longer biologic progression-free survival (PFS), radiologic PFS, higher biologic and radiologic response rates, and had higher pain-control rates than patients receiving placebo. The survival benefit was seen in all age groups (<65, ≥65, and ≥75 years of age). Toxicity was mild: 33 % developed edema (versus 24 % in the placebo arm), 18 % hypokalemia (versus 9 %), 11 % hypertension (versus 8 %), and 16 % cardiac disorders (versus 12 %).
There are limited data on the use of abiraterone in patients with cardiac comorbidities. This is a frequent problem in elderly patients and may be unbalanced by the mineralocorticoid effect of abiraterone. Data from a monocentric retrospective experience seem to suggest that it is possible to use it. 25 However most of these patients had hypertension only and few patients had other cardiac conditions (arrhythmia, ischemia). More data are needed.
The other phase III trial (COU-AA-302) compared abiraterone + prednisone to placebo + prednisone in patients with mCRPC who were asymptomatic or mildly symptomatic (i.e. who did not require level II or III analgesics) and who were chemo-naïve. 24 Median age in the trial was 71 years (44-95) and nearly one-third of the patients were 75 years of or older. There again, adequate cardiac, renal, and liver function were required.
The trial was stopped after a planned interim analysis showed a clear benefit in radiologic PFS, one of the co-primary endpoints (HR=0.53, 95 % CI 0.45-0.62); p<0.001). Analysis of all the secondary endpoints (biologic and radiologic response rates, median time to opiate use, median time to chemotherapy initiation, and median time to PS decline ≥1) favored abiraterone. However the second co-primary endpoint (OS) did not reach the preplanned statistical significance (HR=0.75, 95 % CI 0.61-0.93; p=0.01).
Toxicity was similar to that already reported. Subgroup analysis showed that the benefit seen in radiologic PFS was present in every age group.
Abiraterone has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in both situations (preand postchemotherapy). It seems to be efficient in elderly patients and tolerable in fit patients. However, drug interactions should be kept in mind.
Kalemia and blood pressure should be closely monitored. Data in patients with comorbidities, as we see in our daily practice are lacking.
Enzalutamide
Enzalutamide, formerly known as MDV3100, is a novel antiandrogen. It binds to the androgen receptor with higher affinity than the first-generation antiandrogen, bicalutamide. It inhibits nuclear translocation of the androgen receptor and its binding to DNA. It also inhibits coactivator recruitment. It appears to be efficient even in older patients. Toxicity is acceptable.
However, caution must be taken in case of increased risk for seizures and when combining it with drugs that may prolong the QTc.
New Chemotherapies-Cabazitaxel
Cabazitaxel is a novel tubulin-binding taxane. toxicity with cabazitaxel is more of a concern than with the new hormone therapies. grade 3 neutropenia occurred in 82 % of patients on cabazitaxel and 8 % had febrile neutropenia; 2 % died of neutropenic fever and its clinical consequences/sepsis. Diarrhea occurred in 47 % of patients (6 % grade 3).
more data on the toxicity of cabazitaxel in elderly patients is available from the european expanded-access program. 28 Only patients with a good PS and no uncontrolled severe disease or medical condition were enrolled. Overall, 736 patients with mcRPc were enrolled: 325 were ≥70 years (among which 145 were ≥75 years) and 421 were <70 years. any grade treatment emergent adverse event (teae) occurred in 88.1 % in patients <70 years and in 89.5 % in patients ≥70 years. grade 3 teae were slightly more frequent in patients ≥70 years (52.9 % versus 47 %). teae led to treatment discontinuation in 19.1 % patients ≥70 years compared with 13.3 % patients <70 years.
toxic deaths rates were similar around 2-2.5 %. elderly patients received more-frequent granulocyte-colony stimulating factor (g-cSF) prophylaxis.
cabazitaxel is an efficient drug-even in fit, elderly patients. However it has side effects that can be quite severe. g-cSF should be used as primary prophylaxis 29 and diarrhea must be managed proactively.
the optimal sequence has not been determined yet. Patients with highgrade gleason scores, short response to androgen deprivation therapy (aDt), and progression on docetaxel probably should receive cabazitaxel if available and if patients are fit enough. However, the data supporting this sequence over using a new hormonal treatment are limited.
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Bone and Prostate Cancer
Bone is the most frequent metastatic site in patients with prostate cancer.
management of bone pain is crucial in treating men with metastatic prostate cancer.
Treating Bone Metastases
Radium-223 is a radioactive calcium mimetic that has been studied in patients with mcRPc who had symptomatic bone metastases and no visceral disease and no large lymph nodes (>3 cm). 36 it is an alphaemitting particle that has an ultralow range of action and is eliminated by the digestive system. events in 11 % patients on radium and 12 % on placebo). this could be an interesting drug for elderly patients with bone metastases from hormoneresistant cancer, but there are no specific data in that population. Oncology group (ecOg) PS, mini-mental Status (mmS), mininutritional assessment (mna), and chemotox. chemothox is a derivative of the maX2 index, which summarizes the overall severe toxicity from a chemotherapy regimen.
Prevention of Skeletal-related Events
Patients fell into four categories with a combined risk for severe toxicity ranging from 60 % in the 'low risk' to over 80 % in the 'high-risk' group. the two models did not find the same criteria. However, geriatric and biologic criteria and chemotherapy characteristics, were found to be predictive in both series. One thing that is noteworthy is that severe toxicity rates are quite high in both series and elderly patients should be monitored closely.
Conclusion
Prostate cancer is frequent in elderly patients. the landscape of mcRPc treatment is changing. the data for the use of the new drugs in the general elderly population are quite scarce. Despite seemingly favourable toxicity profiles of the new hormone therapies, drug interactions, and comorbidity should be assessed and patients closely monitored for side effects and treatment benefit. applying the therapeutic changes to elderly patients with mcRPc requires developing tools that can easily assess the general status of patients and predict toxicity. it also requires having large datasets on the drug in less-fit elderly patients. the ideal situation would be having specific prospective trials that would integrate geriatric evaluation, prospective evaluation of toxicity scores, and evaluation of new drugs. n
